Business Wire

Fluence by OSRAM Reveals Multiyear Global Research Results on Broad-Spectrum Lighting Strategies for Cannabis and Food Crops

12.8.2021 15:00:00 EEST | Business Wire | Press release

Share

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the results from a series of multiyear global studies analyzing the effects of broad-spectrum white light on cannabis, Merlice tomatoes and bell peppers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005279/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence by OSRAM announced results from a series of multiyear global studies analyzing the effects of broad-spectrum white light on plant yield, morphology, development and quality in cannabis, Merlice tomato and bell pepper crops. (Photo: Business Wire)

The studies found that while spectrum sensitivity is cultivar-dependent, broad-spectrum lighting strategies—which include green light and other wavelengths largely absent in narrow-band spectra—improved crop yield, morphology and overall performance in selected cultivars when compared to narrow-band spectra with high ratios of red and far-red wavelengths.

“The results from our global studies show how effective broad-spectrum white light can be in improving crop performance for many cultivators around the world,” said Dr. David Hawley, principal scientist at Fluence. “Broad-spectrum strategies are about balance and flexibility in the spectrum itself as well as the overall cultivation approach. While there are certain scenarios in which narrow-band spectra, or pink light, may make sense from an energy efficiency or crop production perspective, we’ve found that many cultivars simply perform better under broad spectra across the KPIs cultivators care about most: yield, morphology and overall quality. Our latest research empowers us with new insights to assess each grower’s objectives, weigh those objectives against a facility’s unique financial, environmental and energy parameters, and then ultimately derive a tailored solution for each cultivator.”

Merlice tomatoes

A collaborative study with Wageningen University and Research (WUR)—led by researchers Leo Marcelis and Ep Heuvelink—evaluated differences in yield, morphology, development and quality for Merlice tomatoes grown with the VYPR top light series under four light spectra: PhysioSpecTM BROAD R4, PhysioSpec TM BROAD R6, PhysioSpecTM BROAD R8 and PhysioSpecTM DUAL R9B. BROAD R4, R6 and R8 all contain significant fractions of green light and other photosynthetically active wavelengths, while DUAL R9B is a narrow-band spectrum that contains almost no green light.

As researchers increased the ratio of red light in the overall spectrum, they recorded a linear decrease in yield. Compared to spectra with higher blue, red and far-red wavelengths, Merlice grown under broader spectrum lights yielded increases in fruit weight as high as 13 percent. Other tomato cultivars grown under broad-spectrum saw yield increases up to 14 percent.

Cannabis

Fluence conducted individual studies with WUR and Texas Original Compassionate Cultivation (TOCC), respectively. In the TOCC study, researchers studied Type I, Type II and Type III cannabis response to broad-spectrum R4, R6 and R8 under high PPFD. In each case, broad-spectrum R4 generated the most dry weight per plant. In Type I cannabis, PhysioSpecTM BROAD R4 generated 17 percent higher yields than the next highest yielding spectral solution, R6. Cannabis grown under broad-spectrum R4 also significantly improved morphology compared to plants cultivated under R6 or R8. Plants grown under broad-spectrum R4 were free of photobleaching in their upper buds, a development that typically occurs in plants grown with a higher fraction of red light.

In the WUR study, researchers found that in some cultivars, monoterpene and cannabinoid content, including THC, CBD and CBG, is significantly inversely proportional to the fraction of red light in the production spectrum. With these cultivars, R4 induced a 20 percent increase in cannabinoid compounds compared to spectra with red light ratios as high as 90 percent or more.

“The results of the TOCC and WUR intensity and spectrum studies are important for cannabis cultivators for two reasons,” Dr. Hawley said. “First, there is rarely a scenario in which they should grow cannabis under low PPFD. Our research continues to emphasize how much more beneficial it is to grow cannabis under higher PPFDs. Second, watch your red light ratio. There are a couple very specific cultivars and production situations that could benefit from narrow-band or high red/far-red and blue wavelengths. But it can also have detrimental effects on cannabinoid content, terpene ratios, yield and morphology, and would raise the risk of significant photobleaching of the canopy. That’s why we generally recommend growing cannabis with broad-spectrum under high PPFD.”

Bell pepper

Fluence also conducted studies with bell peppers at the Harrow Research and Development Centre in Ontario, Canada led by Dr. Xiuming Hao and Dr. Jason Lanoue. The collaborative research on bell pepper found that fruit quality significantly increased in Gina and Eurix cultivars under broad-spectrum lighting. Peppers grown under broader spectrum light increased average fruit size by up to 15 percent compared to others with higher blue and red wavelengths. An increase in the dry matter content—which is largely associated with fruit quality—also increased with increasing green light. It was also found that broad-spectrum lighting strategies proved the consistency of week-to-week production by leveling out a traditionally flush-prone crop cycle.

“Time and time again, our research with leading institutions around the world is proving that there is no universal spectral strategy for cultivators,” said David Cohen, CEO at Fluence. “For many crops and cultivars, however, it’s also showing the holistic benefits of broad-spectrum white light not just for the crop, but for a cultivator’s entire operation. That’s why we at Fluence have a multilayered approach to how we work with our cultivators. We continue to invest heavily in industry-leading research around the world. We provide cultivators with boots-on-the-ground expertise and experience in the form of our horticulture services team, and we identify the right light fixture and spectral strategy to help cultivators achieve their most important goals.”

Fluence’s ongoing global research initiatives include additional studies on strawberry, lettuce and cucumber cultivation. To learn more about Fluence and discover its latest research results, visit www.fluence.science.

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fluence, Emma Chase
pr@fluencebioengineering.com
C: 512-917-4319

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release

Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release

For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye